Using alternative xeno nucleic acids for cell specific targeting
Status
Founded
Development stage
Xterna is developing cell specific binders that are composed of xeno nucleic acids (XNA). By focusing on cell types that evade protein antigen based targeting approaches, it's able to unlock new cell types for targeted drug delivery.